180 related articles for article (PubMed ID: 37870435)
1. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Huntington SF; de Nigris E; Puckett J; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong E; Leng S; Yang X; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2286-2295. PubMed ID: 37870435
[TBL] [Abstract][Full Text] [Related]
2. Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.
Huntington SF; de Nigris E; Puckett JT; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong EM; Leng S; Yang X; Doshi JA
Cancer Med; 2024 Jan; 13(2):e6953. PubMed ID: 38348963
[TBL] [Abstract][Full Text] [Related]
3. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
5. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
6. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
9. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
Huntington SF; Manzoor BS; Puckett JT; Kamal-Bahl S; Alhasani H; Ravelo A; Jawaid D; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2316-2323. PubMed ID: 37732602
[TBL] [Abstract][Full Text] [Related]
10. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
[No Abstract] [Full Text] [Related]
11. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
12. Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada.
Khelifi RS; Huang SJ; Savage KJ; Villa D; Scott DW; Ramadan K; Connors JM; Sehn LH; Toze CL; Gerrie AS
Leuk Lymphoma; 2023 Jun; 64(6):1129-1138. PubMed ID: 37086469
[TBL] [Abstract][Full Text] [Related]
13. Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution.
Sekiguchi Y; Iizuka H; Takizawa H; Mitsumori T; Tomita S; Izumi H; Okubo M; Miyake K; Osawa T; Sawada T; Yoshikawa S; Noguchi M
Gan To Kagaku Ryoho; 2021 Jul; 48(7):921-926. PubMed ID: 34267029
[TBL] [Abstract][Full Text] [Related]
14. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
15. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
16. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
[TBL] [Abstract][Full Text] [Related]
17. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
Omi A; Nomura F; Tsujioka S; Fujino A; Akizuki R
J Clin Exp Hematop; 2022 Sep; 62(3):136-146. PubMed ID: 35831100
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Martino EA; Mauro FR; Reda G; Laurenti L; Visentin A; Frustaci A; Vigna E; Pepe S; Catania G; Loseto G; Murru R; Chiarenza A; Sportoletti P; Del Principe MI; Laureana R; Coscia M; Galimberti S; Ferretti E; Zucchetto A; Bomben R; Polesel J; Tedeschi A; Rossi D; Trentin L; Neri A; Morabito F; Gattei V; Gentile M
Hematol Oncol; 2024 Jan; 42(1):e3249. PubMed ID: 38287529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
